[BREAKING] Trump announces 100% tariff on branded or patented pharmaceutical imports from Oct 1

sango65

sango65

Master Member
Joined
Oct 21, 2013
Messages
3,292
Reaction score
2,293
https://www.channelnewsasia.com/wor...s-us-trucks-furniture-home-renovation-5370396

Trump announces 100% tariff on branded or patented pharmaceutical imports from Oct 1​

The US president also announced new tariffs on trucks, home renovation fixtures and furniture.

WASHINGTON: United States President Donald Trump announced on Thursday (Sep 25) new tariffs on pharmaceuticals, big-rig trucks, home renovation fixtures and furniture.

Starting Oct 1 "we will be imposing a 100 per cent Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America," the Republican wrote on his Truth Social platform.

In a separate post, he wrote of a 25 per cent tariff on "all 'Heavy (Big) Trucks' made in other parts of the world" to support US manufacturers such as "Peterbilt, Kenworth, Freightliner, Mack Trucks and others".

He said the truck tariffs were "for many reasons, but above all else, for National Security purposes!"

Earlier this year, the Trump administration launched a probe into imports of trucks to "determine the effects of national security".

The real estate tycoon also targeted home renovation materials, writing "We will be imposing a 50 per cent Tariff on all Kitchen Cabinets, Bathroom Vanities and associated products" as of Oct 1.

"Additionally, we will be charging a 30 per cent Tariff on Upholstered Furniture," he added.
 
Courage

Courage

Arch-Supremacy Member
Joined
May 23, 2016
Messages
20,576
Reaction score
9,929
Truck factory can be converted into transport vehicle and tanks during war but tanks are now obsolete. US is so 1940s
 
wwenze

wwenze

Greater Supremacy Member
Joined
Dec 2, 2002
Messages
84,659
Reaction score
28,573
Lol using other countries trick back on them

(Hint: Check where Singapore imports vaccines from and how much tariff or rather straight up bans they have. Also they have law that says no copyright for medicine so they don't even pay the original creator any licensing fee i.e. pirated medicine?/)
 
0nePunchm@n

0nePunchm@n

Senior Member
Joined
Jan 18, 2025
Messages
2,432
Reaction score
1,773
See here got many King dumb trump supporters.. See how he hurt us now.. happy liao :(
 
Braun8

Braun8

Master Member
Joined
Mar 23, 2012
Messages
4,457
Reaction score
3,493
Wah, the 100% tariff on pharmaceuticals will really hurt SG and could cause a recession

Pharmaceutical companies will move production to US for the US market
 
S

stanlawj

Supremacy Member
Joined
Jul 11, 2021
Messages
9,108
Reaction score
4,871

Key Pharmaceutical Companies in Singapore Potentially Affected​


  1. Pfizer
    • Presence: Pfizer has a significant manufacturing presence in Singapore, with a 429,000-square-foot plant in Tuas Biomedical Park producing active pharmaceutical ingredients (APIs) for cancer, pain, and antibiotic medications. It established its presence in Singapore in 1964 and is a top pharmaceutical manufacturer there [Built In Singapore, 2024-09-20].
    • Impact: Pfizer exports APIs and finished drugs to the U.S., which is one of its major markets. The tariff could pressure Pfizer to either accelerate or initiate new U.S.-based manufacturing to avoid the 100% levy, potentially reducing its reliance on Singapore for U.S.-bound production. Given its existing global supply chain, Pfizer might already have U.S. facilities, but any Singapore-produced branded drugs (e.g., those under patents like anti-infectives) could face tariffs unless construction of a new U.S. plant has started by the deadline.
  2. AstraZeneca
    • Presence: AstraZeneca is building a $1.5 billion manufacturing facility in Singapore for antibody-drug conjugates (ADCs), a category of cancer-killing drugs, with operations expected to begin in 2029. This will be its first end-to-end ADC production site [Reuters, 2024-05-20].
    • Impact: While the Singapore facility is under construction (qualifying it for a tariff exemption under the "IS BUILDING" definition of "breaking ground" or "under construction"), any branded or patented drugs currently exported from Singapore to the U.S. (e.g., existing products like Enhertu, manufactured by partner Daiichi Sankyo in Japan but distributed globally) could face tariffs unless U.S. manufacturing is underway. AstraZeneca may need to expedite U.S. plant construction to maintain its U.S. market share for other products.
  3. Amgen
    • Presence: Amgen opened its first Asian manufacturing facility in Singapore in 2014 and a commercial chemical synthesis plant in 2015. Singapore serves as its Asia Pacific regional headquarters [Built In Singapore, 2024-09-20].
    • Impact: Amgen exports biologic therapies (e.g., Enbreal for autoimmune diseases and Repatha for cholesterol management) to the U.S. The tariff could affect these branded products unless Amgen has or starts building U.S. manufacturing plants. Given its U.S. base (California), Amgen may already have domestic production, but Singapore-made exports could be at risk.
  4. Eli Lilly
    • Presence: Eli Lilly has a significant presence in Singapore, handling wholesale distribution of prescription and proprietary drugs across the Asia Pacific region. It develops compounds for over 40 disease areas [Built In Singapore, 2024-09-20].
    • Impact: Eli Lilly exports branded drugs like Mounjaro (for diabetes and weight loss) and Cialis to the U.S. If these are manufactured in Singapore or other non-U.S. locations, the 100% tariff will apply unless U.S. plant construction begins. Lilly, based in Indiana, likely has U.S. facilities, but Singapore’s role in distribution and potential manufacturing could be affected if production shifts.
  5. Bayer
    • Presence: Bayer’s Singapore office serves as the regional headquarters for the Asia Pacific market, covering pharmaceuticals, crop science, and consumer health. It produces drugs like Aspirin and Claritin [Built In Singapore, 2024-09-20].
    • Impact: Bayer exports branded pharmaceuticals and over-the-counter products to the U.S. The tariff could impact Singapore-produced branded drugs unless Bayer initiates U.S. manufacturing. As a German company, Bayer has global facilities, but Singapore’s export role may diminish if it prioritizes U.S. production to avoid the tariff.
  6. Schwabe Pharma Asia Pacific
    • Presence: A subsidiary of the Schwabe Group, it focuses on homeopathic and herbal medicines, operating out of Singapore since 2005 [Built In Singapore, 2024-09-20].
    • Impact: If Schwabe exports patented or branded herbal medicines to the U.S. from Singapore, it could face the tariff. As a niche player, its ability to build a U.S. plant may be limited, potentially forcing it to redirect exports or absorb the cost increase.
  7. APD Pharmaceutical Manufacturing Pte Ltd
    • Presence: A GMP-certified contract manufacturer in Singapore with 16+ years of experience, offering private-label products and one-stop services including product development and registration [apd.com.sg, 2025-04-16].
    • Impact: APD manufactures for other companies and could be affected if its clients export branded or patented drugs to the U.S. The tariff might push APD’s partners to shift production to the U.S., reducing demand for Singapore-based contract manufacturing unless APD itself invests in U.S. facilities (unlikely given its scale).

Broader Considerations​

  • Export Dependency: Singapore exports more pharmaceuticals than it imports, with the U.S., Europe, and Japan as key markets. The tariff could disrupt this balance, especially since U.S. demand for APIs and drugs surged during the pandemic [Reuters, 2020-05-27].
  • Construction Exemption: Companies with plants "under construction" in the U.S. by October 1, 2025, are exempt. Firms like AstraZeneca (with its Singapore plant) may leverage this, but others must act quickly to start U.S. projects.
  • Market Response: The Monetary Authority of Singapore has highlighted that 40% of U.S.-bound exports (including drugs) are at risk, suggesting a potential shift in global supply chains [Reuters, 2025-04-28]. Companies may relocate production or raise prices, impacting Singapore’s biomedical sector, which employs 24,000+ people [Reuters, 2020-05-27].

Likely Affected Companies​

The most affected companies will be those with significant U.S. exports of branded or patented drugs from Singapore without current or planned U.S. manufacturing. Pfizer, Amgen, Eli Lilly, and Bayer are particularly vulnerable due to their large-scale operations and U.S. market presence. AstraZeneca may be partially shielded by its ongoing U.S. expansion plans, while smaller players like Schwabe Pharma and APD could face indirect pressure through client decisions.


Recommendation​

These companies should assess their U.S. manufacturing status and consider initiating construction by the deadline to avoid the tariff. Alternatively, they might redirect exports to other markets (e.g., Europe, Japan) or negotiate with the U.S. government for exemptions, though the latter seems unlikely based on the firm stance in the announcement. Monitoring updates from the White House and U.S. trade policy will be critical in the coming weeks.
 
Last edited:
S

stanlawj

Supremacy Member
Joined
Jul 11, 2021
Messages
9,108
Reaction score
4,871
Competitive Threat Posed by Chinese biotech and pharmaceutical companies

Given the current date and time (09:16 AM +08, Friday, September 26, 2025), and the White House's announcement of a 100% tariff on branded or patented pharmaceutical products from October 1, 2025, unless companies build manufacturing plants in the U.S., Singapore-based pharmaceutical companies like Pfizer, Amgen, Eli Lilly, Bayer, AstraZeneca, Schwabe Pharma, and APD Pharmaceutical Manufacturing may redirect exports to the Asia-Pacific region to mitigate the impact. This shift could intensify competition with China-based or Chinese biotech and pharmaceutical companies, which have been strategically expanding their presence in the region. Below is an assessment of how Chinese firms might pose a competitive threat to these Singaporean operations.

Context of China’s Pharmaceutical Industry​

  • Market Growth: China’s pharmaceutical market is the second-largest globally, valued at approximately $170 billion in 2023, with a projected compound annual growth rate (CAGR) of 6-8% through 2030 [Evaluate, 2025-02-25; Reuters, 2025-08-13]. The Asia-Pacific region, including China, accounts for a growing share of global pharmaceutical demand.
  • Export Strength: China exported $13.7 billion in pharmaceuticals to ASEAN countries along the Belt and Road Initiative (BRI) in 2022, up from $4.8 billion in 2013, and is the largest supplier of active pharmaceutical ingredients (APIs) to Southeast Asia [Carnegie Endowment, 2025-01-23].
  • Government Support: China’s government backs its biotech sector with subsidies, tax incentives, and the “Made in China 2025” initiative, aiming to make it a global leader in biopharmaceuticals [Reuters, 2025-08-13].
  • Southeast Asia Pivot: Amid U.S. scrutiny (e.g., the proposed Biosecure Act targeting firms like BGI and WuXi Biologics), Chinese companies are diversifying into Southeast Asia, leveraging proximity and regional trade networks [Carnegie Endowment, 2025-01-23].

Competitive Threats from Chinese Biotech and Pharmaceuticals​

  1. Cost Advantage
    • Analysis: Chinese firms like Shanghai Titan Scientific and Nanjing Vazyme Biotech benefit from lower labor and production costs, with local reagent markets growing over 10% annually [Reuters, 2025-08-13]. This allows them to offer competitive pricing on generics, APIs, and even some branded drugs.
    • Impact on Singapore: Singapore-based firms, reliant on high-tech manufacturing and a skilled workforce, face higher operational costs (e.g., Singapore’s biomedical sector employs 24,000+ with advanced facilities [Reuters, 2020-05-27]). If Chinese firms undercut prices in Asia-Pacific markets, Singaporean companies may lose market share, especially for cost-sensitive generics and APIs.
    • Example: Titan’s revenue is forecast to grow 22% to $490 million in 2025 [Reuters, 2025-08-13], potentially outpacing smaller Singaporean contract manufacturers like APD.
  2. Supply Chain Integration
    • Analysis: China’s dominance in API supply (e.g., to Indonesia, Thailand, Vietnam) and its integration into ASEAN supply chains via the China-ASEAN Free Trade Agreement (FTA) give it a logistical edge [Carnegie Endowment, 2025-01-23]. Singapore, while a hub, relies on imported raw materials, which could become costlier if global supply chains shift.
    • Impact on Singapore: Companies like Pfizer and Amgen, which produce APIs in Singapore, may face higher input costs or delays compared to Chinese competitors with local sourcing. This could weaken their competitiveness in regional markets like Malaysia or Indonesia.
    • Example: China’s $5.76 billion reagent import market in 2024 [Reuters, 2025-08-13] shows its ability to pivot to domestic supply, a flexibility Singapore lacks due to its import dependency.
  3. Innovation and R&D
    • Analysis: Chinese firms are investing heavily in R&D, with companies like WuXi Biologics and BGI advancing in biologics and genomics. The government’s support for biopharma innovation is driving patents and new drug development [Carnegie Endowment, 2025-01-23].
    • Impact on Singapore: Singapore’s strength lies in its regulatory environment and intellectual property (IP) protection (e.g., Singapore’s Patent Prosecution Highway network [Carnegie Endowment, 2025-01-23]), attracting global R&D. However, if Chinese firms develop competitive branded drugs or biosimilars faster and cheaper, they could challenge Singaporean firms like AstraZeneca (building an ADC plant) or Amgen (biologics focus) in the Asia-Pacific.
    • Example: WuXi Biologics’ global capacity expansion could rival Amgen’s Singapore-made biologics if priced lower in regional markets.
  4. Market Penetration and Partnerships
    • Analysis: Chinese companies are leveraging Southeast Asia’s growing biopharma sector (e.g., Singapore’s Economic Development Board reports 79 of the top 100 global pharma firms in the region [Carnegie Endowment, 2025-01-23]) through partnerships and investments. Singapore’s role as a hub could be undermined if Chinese firms establish manufacturing bases in countries like Indonesia or Thailand.
    • Impact on Singapore: Firms like Eli Lilly and Bayer, which use Singapore for distribution, may see reduced demand if Chinese competitors build regional production closer to end markets. The 2022 ASEAN Pharmaceutical Regulatory Policy (APRP) could facilitate this shift [Carnegie Endowment, 2025-01-23].
    • Example: Chinese investments in Indonesia’s medicinal resources could bypass Singapore’s distribution networks.
  5. Response to U.S. Tariffs
    • Analysis: The U.S. tariff push mirrors China’s own import tariff hikes (e.g., 125% on U.S. goods in April 2025, later lowered [Reuters, 2025-08-13]), prompting Chinese firms to focus on domestic and regional markets. This alignment could accelerate their Asia-Pacific dominance.
    • Impact on Singapore: As Singaporean firms redirect exports, they’ll compete directly with Chinese firms already entrenched in these markets. The tariff-driven shift might favor Chinese players with established regional footholds.
    • Example: FujiFilm’s potential benefit from U.S. tariffs [X Post @grenoille8, 00:37 2025-09-26 UTC] suggests Japanese firms could also enter, but Chinese firms’ scale gives them an edge.

Strategic Implications for Singaporean Companies​

  • Short-Term Risks: In the immediate term (post-October 1, 2025), Singaporean firms may lose pricing power and market share to cheaper Chinese alternatives, especially in generics and APIs. Smaller players like Schwabe Pharma and APD could be squeezed out.
  • Long-Term Opportunities: Singapore’s advanced infrastructure, IP protection, and regulatory alignment (e.g., Pharmaceutical Inspection Co-operation Scheme membership [Carnegie Endowment, 2025-01-23]) could attract redirected global R&D if Chinese firms face geopolitical risks. Firms like AstraZeneca (with its new ADC plant) could leverage this.
  • Mitigation Strategies: Singaporean companies should:
    • Diversify Markets: Target non-Asia-Pacific regions (e.g., Europe) to reduce reliance on the region.
    • Cost Optimization: Partner with local Asian suppliers to compete on price.
    • Innovation Focus: Accelerate R&D in niche areas (e.g., ADCs, biologics) where China lags.

Conclusion​

China-based biotech and pharmaceutical companies pose a significant competitive threat to Singaporean firms redirecting exports to the Asia-Pacific, driven by cost advantages, supply chain integration, growing R&D, and market penetration. Companies like Pfizer, Amgen, and Eli Lilly will face the toughest challenges due to their scale, while AstraZeneca’s ongoing U.S. and Singapore investments may offer a buffer. The next few months will be critical as Singaporean firms adapt to this tariff-induced shift, with China poised to capitalize on its regional strengths unless countered by strategic repositioning.
 
AndroidComa

AndroidComa

Arch-Supremacy Member
Joined
Jan 13, 2021
Messages
15,481
Reaction score
7,454
JAson1980 said:
LOL so many expansion in the past 5 years. all die now ah?
Click to expand...
wun die lah
as long as the same company has started work in a US plant, they are exempted i read...



Investing.com-- U.S. President Donald Trump on Thursday evening announced a slew of new trade tariffs, most notably a 100% levy on the import of pharmaceutical products.

The levies also include a 25% tariff on heavy truck imports, a 50% tariff on kitchen and bathroom fittings, and a 30% tariff on upholstered furniture. Trump said they will take effect from October 1.

Trump said in a social media post that the pharma tariffs will apply to any "branded or patented Pharmaceutical Product."

But he added that any companies building manufacturing plants in the U.S. will be exempt from the tariffs, specifying that the companies needed to have at least broken ground or started constructing U.S. facilities.
 
JAson1980

JAson1980

High Supremacy Member
Joined
Feb 27, 2006
Messages
43,218
Reaction score
3,032
That buffon just mentioned that the Amish community has zero Autism because they don't take any vaccines. :s22::s22::s22:
 
U

Ubi-Warrior

High Supremacy Member
Joined
Jan 29, 2020
Messages
33,989
Reaction score
7,723
sango65 said:
https://www.channelnewsasia.com/wor...s-us-trucks-furniture-home-renovation-5370396

Trump announces 100% tariff on branded or patented pharmaceutical imports from Oct 1​

The US president also announced new tariffs on trucks, home renovation fixtures and furniture.

WASHINGTON: United States President Donald Trump announced on Thursday (Sep 25) new tariffs on pharmaceuticals, big-rig trucks, home renovation fixtures and furniture.

Starting Oct 1 "we will be imposing a 100 per cent Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America," the Republican wrote on his Truth Social platform.

In a separate post, he wrote of a 25 per cent tariff on "all 'Heavy (Big) Trucks' made in other parts of the world" to support US manufacturers such as "Peterbilt, Kenworth, Freightliner, Mack Trucks and others".

He said the truck tariffs were "for many reasons, but above all else, for National Security purposes!"

Earlier this year, the Trump administration launched a probe into imports of trucks to "determine the effects of national security".

The real estate tycoon also targeted home renovation materials, writing "We will be imposing a 50 per cent Tariff on all Kitchen Cabinets, Bathroom Vanities and associated products" as of Oct 1.

"Additionally, we will be charging a 30 per cent Tariff on Upholstered Furniture," he added.
Click to expand...

What if after tariff the imports are still cheaper and better than those manufactured in the US?

Cant beat raising taxes under the guise of self-preservation I suppose.
 
You must log in or register to reply here.
Important Forum Advisory Note
This forum is moderated by volunteer moderators who will react only to members' feedback on posts. Moderators are not employees or representatives of HWZ Forums. Forum members and moderators are responsible for their own posts. Please refer to our Community Guidelines and Standards and Terms and Conditions for more information.
Top